Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Nov 13, 2024 · 10-Q · 44 days after period end · 0001140361-24-046312
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$3.43M | -$3.27M | -$4.93M | $981.00K |
| EPS Diluted | -$0.30 | -$0.43 | -$0.11 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end
